The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.
 
Stephen Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech; Gilead Sciences; GlaxoSmithKline; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merus; Mirati Therapeutics; MSD Oncology; Natera; Novartis; OSE Immunotherapeutics; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Takeda; Yuhan
Research Funding - Abbvie (Inst); Alkermes (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Cogent Biosciences (Inst); Duality Biologics (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Systimmune (Inst)
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Cyril Guibert
Research Funding - Amgen (Inst); Gilead Sciences (Inst); MSD (Inst); OSE Immunotherapeutics (Inst)
Travel, Accommodations, Expenses - Chiesi; Menarini; Sanofi/Regeneron
 
Elvire Pons Tostivint
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Janssen; Roche; Sanofi Pasteur; Takeda
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Pfizer; Roche/Genentech; Sanofi; Takeda
 
Raffaele Califano
Stock and Other Ownership Interests - LOC @ TCPC; supportive care UK
Honoraria - AstraZeneca; GlaxoSmithKline; Janssen Oncology; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - Janssen; PharmaMar
Speakers' Bureau - Janssen; Takeda
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); MSD (Inst); PharmaMar (Inst); roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Takeda
 
Ludovic Doucet
Travel, Accommodations, Expenses - MSD
 
Thomas Egenod
No Relationships to Disclose
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oology; Pfizer; Roche/Genentech
Consulting or Advisory Role - GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer
 
Santiago Viteri Ramirez
Consulting or Advisory Role - Affimed Therapeutics; Bristol-Myers Squibb; Ipsen; Janssen; Merck KGaA; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; MSD
Travel, Accommodations, Expenses - OSE Immunotherapeutics; Roche
 
Federico Cappuzzo
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; bristol-myers; Illumina; Lilly; MSD Oncology; Novocure; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda; Thermofisher Scientific Biomarkers
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure; pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Travel, Accommodations, Expenses - OSE Immunotherapeutics
 
Silvia Comis
Employment - OSE Immunotherapeutics
Leadership - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
 
Caroline Chevalier
Employment - OSE Immunotherapeutics
 
Valerie Gabarre
Employment - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
 
Thomas Vandewalle
Employment - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
Patents, Royalties, Other Intellectual Property - Predictive efficacy biomarkers for anti-SIRPa antibodies
 
François Montestruc
No Relationships to Disclose
 
Berangere Vasseur
Employment - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
Patents, Royalties, Other Intellectual Property - Patent "USES OF ANTI-SIRPa ANTIBODIES IN THE TREATMENT OF CANCER"
 
Jordi Remon Masip
Consulting or Advisory Role - AstraZeneca (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); OSE Immunotherapeutics
Travel, Accommodations, Expenses - AstraZeneca; Inivata; MSD Oncology; OSE Immunotherapeutics; OSE Immunotherapeutics; Roche/Genentech
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Sanofi/Aventis (Inst); SERVIER (Inst)
Consulting or Advisory Role - Abbvie (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Enliven Therapeutics (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Takeda (Inst)